Kiora Pharmaceuticals Inc (KPRX): Depreciation & Amortization
$24.8K
Year ended 2025-12-31
$42.4K
Trailing 12 months to 2026-06-30
-15.8%
3-year compound annual growth
-5.8%
5-year compound annual growth
+34.7%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.8K | +29.1% | 2026-03-25, From 2025-01-01 |
| 2024-12-31 | $19.2K | -62.9% | 2026-03-25, From 2024-01-01 |
| 2023-12-31 | $51.8K | +24.5% | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | $41.6K | -8.1% | 2024-03-25, From 2022-01-01 |
| 2021-12-31 | $45.3K | +35.6% | 2023-03-23, From 2021-01-01 |
| 2020-12-31 | $33.4K | -35.4% | 2022-07-07, From 2020-01-01 |
| 2019-12-31 | $51.7K | +34.3% | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | $38.5K | +99.5% | 2020-03-04, From 2018-01-01 |
| 2017-12-31 | $19.3K | +272.0% | 2019-03-01, From 2017-01-01 |
| 2016-12-31 | $5.2K | +312.5% | 2018-03-02, From 2016-01-01 |
| 2015-12-31 | $1.3K | -27.1% | 2017-02-23, From 2015-01-01 |
| 2014-12-31 | $1.7K | n/a | 2016-03-30, From 2014-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $24.8K | +29.1% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $4.01B | -58.2% |
| TherapeuticsMD, Inc. (TXMD) | 2025-12-31 | $384.0K | -24.6% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $2.00B | +13.0% |
| Pfizer Inc (PFE) | 2025-12-31 | $6.59B | -6.0% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $7.50B | +2.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $13.84M | -2.6% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | $146.0K | -16.1% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $2.31M | -7.1% |
Compare KPRX, BMY, TXMD, LLY side by side · Screen every company in Pharmaceutical Preparations ↗